Alto Neuroscience, Inc. (NYSE:ANRO) Receives Consensus Rating of “Buy” from Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has been given a consensus rating of “Buy” by the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued a report on the stock in the last year is $33.80.

A number of equities research analysts recently commented on the company. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Rodman & Renshaw initiated coverage on shares of Alto Neuroscience in a research note on Friday, June 21st. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Alto Neuroscience in a report on Tuesday, September 10th.

Alto Neuroscience Trading Up 1.8 %

NYSE:ANRO opened at $10.19 on Friday. The company’s 50 day moving average is $11.61 and its two-hundred day moving average is $12.77. Alto Neuroscience has a twelve month low of $7.91 and a twelve month high of $24.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 19.85 and a quick ratio of 19.85.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. On average, sell-side analysts expect that Alto Neuroscience will post -2.63 EPS for the current fiscal year.

Insider Transactions at Alto Neuroscience

In other Alto Neuroscience news, insider Adam Savitz purchased 12,069 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The stock was purchased at an average price of $12.60 per share, for a total transaction of $152,069.40. Following the purchase, the insider now directly owns 36,920 shares in the company, valued at $465,192. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Institutional Investors Weigh In On Alto Neuroscience

Institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers acquired a new position in Alto Neuroscience during the second quarter worth $113,000. Federated Hermes Inc. lifted its stake in Alto Neuroscience by 33.3% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $128,000 after buying an additional 3,000 shares in the last quarter. University of Texas Texas AM Investment Managment Co. acquired a new stake in Alto Neuroscience in the 1st quarter worth about $340,000. Bank of New York Mellon Corp purchased a new stake in Alto Neuroscience during the 2nd quarter worth approximately $252,000. Finally, Bowie Capital Management LLC acquired a new position in shares of Alto Neuroscience during the second quarter valued at approximately $462,000.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.